布地奈德福莫特罗粉吸入剂联合噻托溴铵吸入粉雾剂对COPD患者CAT评分及痰液TIMP-1、MMP-9表达的影响  

Effects of budesonide Formoterol powder inhaler combined with Tiotropium bromide inhaler aerosol on CAT score and expression of TIMP-1 and MMP-9 in sputum of patients with COPD

作　　者：孙晓莉 赵峰 樊兵权 SUN Xiao-li(Xuchang Hospital of Traditional Chinese Medicine,Xuchang 461000,Henan,China)

机构地区：[1]许昌中医院心肺二科,河南许昌461000

出　　处：《牡丹江医学院学报》2024年第2期54-57,39,共5页Journal of Mudanjiang Medical University

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ20210945)。

摘　　要：目的研究布地奈德福莫特罗粉吸入剂联合噻托溴铵吸入粉雾剂对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者慢性阻塞性肺疾病评分(COPD Assessment Test,CAT)及痰液金属蛋白酶组织抑制因子-1(metalloproteinase-1,TIMP-1)、基质金属蛋白酶9(matrix metalloproteinase 9,MMP-9)表达的影响。方法以我院收治的70例COPD患者为研究对象(2020年1月至2023年1月),采用随机数字表法将患者分为参照组(35例)和联合组(35例)。参照组采用布地奈德福莫特罗粉吸入剂治疗,联合组采用布地奈德福莫特罗粉吸入剂联合噻托溴铵吸入粉雾剂治疗。比较两组临床疗效、治疗前后CAT评分、圣·乔治呼吸调查问卷(St·George’s Respiratory Questionnaire,SGRQ)评分、肺功能指标[最大肺活量(Maximum vital capacity,FVC)、第一秒用力呼气容积(Forced expiratory volume in the first second,FEV_(1))、FEV_(1)/FVC]、诱导痰TIMP-1、MMP-9水平及血清CX3趋化因子配体l(CX3 chemokine ligand l,CX3CLl)、CX趋化因子配体10(CX chemokine ligand 10,CXCL10)水平、不良反应发生率。结果两组临床总有效率比较,联合组(94.29%)高于参照组(74.29%),差异具有统计学意义(P<0.05);与参照组相比,治疗后联合组CAT、SGRQ评分较低,差异具有统计学意义(P<0.05);与治疗前相比,各组治疗后FVC、FEV1、FEV1/FVC明显升高,其中联合组改善更为显著,差异具有统计学意义(P<0.05);治疗后联合组诱导痰TIMP-1、MMP-9水平及血清CX3CLl、CXCL10明显降低,差异具有统计学意义(P<0.05);联合组不良反应总发生率(14.29%)与参照组(8.57%)相比,差异无统计学意义(P>0.05)。结论布地奈德福莫特罗联合噻托溴铵治疗COPD可降低患者CAT评分及痰液TIMP-1、MMP-9水平,提高患者生活质量,改善肺功能指标,抑制炎症反应。Objective To investigate the effects of budesonide formoterol powder inhalant combined with Tiotropium bromide inhalant spray on chronic obstructive pulmonary disease(COPD)score(CAT)and expression of tissue inhibitor of metalloproteinase-1(TIMP-1)and matrix metalloproteinase 9(MMP-9)in sputum of patients with COPD.Methods Seventy COPD patients admitted to our hospital were used as the study population(from January 2020 to January 2023),and the patients were divided into the control group(35 cases)and the combination group(35 cases)using the random number table method.The control group was treated with budesonide formoterol powder inhalation and the combination group was treated with budesonide formoterol powder inhalation combined with tiotropium bromide inhalation powder nebulizer.The clinical efficacy,CAT score,St.George’s Respiratory Questionnaire(SGRQ)score,lung function parameters[maximum lung volume(FVC),first second expiratory volume(FEV1),FEV1/FVC],induced sputum TIMP-1,MMP-9 levels and serum CX3 chemokine ligand l(CX3CLl),CX chemokine ligand 10(CXCL10)levels and the incidence of adverse reactions were compared between the two groups.Results Comparing the total clinical efficiency of the two groups,the combined group(94.29%)was higher than the control group(74.29%),the difference was statistically significant(P<0.05);compared with the control group,the CAT and SGRQ scores were lower in the combined group after treatment,the difference was statistically significant(P<0.05);compared with the pre-treatment,the FVC,FEV1,FEV1/FVC were significantly higher in each group after treatment.More significant improvement was observed in the combined group(P<0.05);the levels of induced sputum TIMP-1 and MMP-9 and serum CX3CLl and CXCL10 were significantly lower in the combined group after treatment(P<0.05);the overall incidence of adverse reactions in the combined group(14.29%)compared with the control group(8.57%)was not statistically significant(P>0.05).Conclusion Budesonide formoterol combined with tiotropium brom

关 键 词：布地奈德福莫特罗 噻托溴铵 COPD 疗效 

分 类 号：R536.9[医药卫生—内科学]